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Abstract
Background
Approval of drugs in chronic hepatitis C is supported by registration trials. These trials might
have limited generalizability through use of strict eligibility criteria. We compared effective-
ness and safety of real world hepatitis C patients eligible and ineligible for registration trials.
Methods
We performed a nationwide, multicenter, retrospective cohort study of chronic hepatitis C
patients treated in the real world. We applied a combined set of inclusion and exclusion crite-
ria of registration trials to our cohort to determine eligibility. We compared effectiveness and
safety in eligible vs. ineligible patients, and performed sensitivity analyses with strict criteria.
Further, we used log binomial regression to assess relative risks of criteria on outcomes.
Results
In this cohort (n = 467) 47% of patients would have been ineligible for registration trials.
Main exclusion criteria were related to hepatic decompensation and co-morbidity (cardiac
disease, anemia, malignancy and neutropenia), and were associated with an increased risk
for serious adverse events (RR 1.45–2.31). Ineligible patients developed significantly more
serious adverse events than eligible patients (27% vs. 11%, p< 0.001). Effectiveness was
decreased if strict criteria were used.
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Conclusions
Nearly half of real world hepatitis C patients would have been excluded from registration tri-
als, and these patients are at increased risk to develop serious adverse events. Hepatic
decompensation and co-morbidity were important exclusion criteria, and were related to
toxicity. Therefore, new drugs should also be studied in these patients, to genuinely assess
benefits and risk of therapy in the real world population.
Introduction
Regulatory approval of drugs and the development of guidelines are supported by evidence
generated by registration trials. These trials aim for high internal validity through use of strict
eligibility criteria, although this may jeopardize generalizability. [1, 2] Some studies suggest
that many real world patients would be excluded from registration trials and that drugs tested
through these trials are less effective or less well tolerated in these patients.[3–5]
The treatment arsenal for chronic hepatitis C patients (CHC) has increased enormously
with the introduction of Direct Acting Antivirals (DAAs). DAAs were approved by regulatory
authorities for use in clinical practice, with evidence coming from registration trials having
strict criteria.[6] Indeed, real world cohorts contain large number of treated CHC patients who
would be excluded from registration trials.[7–10] A lack of generalizability is only an issue
when ineligible patients have worse outcomes, but this is not known for CHC. We hypothesize
that CHC patients ineligible for trials, but who are treated in clinical practice have characteris-
tics that are risk factors for treatment failure and toxicity.
Therefore, we aim to compare effectiveness and safety in real world CHC patients who are
eligible or ineligible for registration trials. Our secondary aim is to identify criteria that impact
trial eligibility and assess the risk of these criteria on outcomes.
Materials and Methods
Population and design
We conducted a nationwide, multicenter, retrospective real world cohort study of CHC
patients in the Netherlands. We chose genotype 1 patients treated between 2011 and 2015 with
telaprevir or boceprevir with peg-interferon and ribavirin as an example cohort. We identified
CHC patients using up-to-date local databases. Treatment indication, choice of therapy, drug
dosing and duration were at the discretion of the physician, following national guidelines. [11]
Patients co-infected with HIV or hepatitis B virus (HBV) were excluded.
Formal evaluation was waived by the institute review board Committee on Research Involv-
ing Human Subjects Arnhem-Nijmegen given the retrospective character of our study. How-
ever, approval in participating centers was obtained according to local regulations. The study
was conducted in accordance with good clinical practice guidelines and the code of conduct for
medical research (www.federa.org). We obtained oral informed consent or collected data anon-
ymously in accordance with the code of conduct for medical research. No identifying patient
data was collected, and all patient data was anonymously entered in the database.
Identification of registration trials and general set of eligibility criteria
We identified registration trials of telaprevir and boceprevir in CHC patients through a system-
atic search (S1 Table). We extracted eligibility criteria from published protocols, and used the
least stringent criteria of all studies to develop a general criteria set (Table 1). We applied the
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Table 1. Set of general eligibility criteria.
Variable Criterion
Inclusion
Age Subject  18 years
Hepatitis C virus (HCV) RNA HCV RNA detectable
Weight Weight between 40–125 kg
Hepatocellular Carcinoma (HCC) Ultrasound with no signs of HCC
Exclusion
Genotype HCV HCV with > 1 subtype or genotype
Hemoglobin Hemoglobin <12 g/dL for females or <13 g/dL for males
Neutrophil count Absolute neutrophil count <1.2 x109/L
Platelet count Platelet count <90 x109/L
Albumin Serum albumin < 3.3 g/dL
Bilirubin Total bilirubin > 1.8x ULN†
International Normalized Ratio (INR) INR 1.5
Thyroid Stimulating Hormone (TSH) TSH > 1.2 x ULN or 0.8x LLN†
Alanine aminotransferase (ALT) ALT 10 x ULN†
Aspartate aminotransferase (AST) AST 10 x ULN†
Contra-indication to peginterferon or
ribavirin
• Hemoglobinopathy
• Cardiac disease
• Renal insufﬁciency
• Hemoglobinopathy present (thallassemia major, sickle-cell disease)
• Signiﬁcant cardiac disease presenta
• Creatinine clearance 50 ml/min
Auto-immune disease Presence of auto-immune diseaseb
Pulmonary disease History of chronic pulmonary disease with impairment (COPD gold III or IV, interstitial lung disease,
pulmonary ﬁbrosis or sarcoidosis)
Current or history of decompensated
liver disease
Current or history of ascites, encephalopathy or bleeding varices
Other liver disease Presence of another liver disease
Malignancy Active malignant disease or malignant disease in past 5 years (except basal cell carcinoma)
Pancreatitis History of acute pancreatitis in past 5 years
Retinopathy Presence of retinopathy
Seizure Presence of a seizure disorder requiring medication
Transplantation Patient with a history of an organ transplant
Psychiatric comorbidity Presence of severe psychiatric diseasec
Corticosteroids Use of systemic corticosteroids
Hemophilia Hemophilia present
Central nervous system (CNS) disorder CNS disorder presentd
Malabsorption History of malabsorption disorder
Indwelling cathether Subject with indwelling venous catheter
Comedication Prohibited comedication listed in protocols
a Signiﬁcant cardiac disease was deﬁned as: current or history of unstable cardiac disease (angina,
congestive heart failure, recent myocardial infarction, pulmonary hypertension, complex congenital heart
disease, cardiomyopathy, and/or signiﬁcant arrhythmia)
bAuto-immune disease was deﬁned as: immunologically mediated disease (inﬂammatory bowel disease,
celiac disease, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus,
autoimmune hemolytic anemia, scleroderma, sarcoidosis, severe psoriasis, or autoimmune hepatitis)
c Psychiatric comorbidity was deﬁned as: severe depression or hospitalization for depression, schizophrenia,
bipolar illness, severe anxiety or personality disorder, a period of disability or impairment due to a psychiatric
disease within the past 5 years
d CNS disorder was deﬁned as: CNS trauma requiring intubation, intracranial pressure monitoring, brain
meningeal/skull surgery, or resulting in seizure, coma, neurologic deﬁcits, abnormal brain imaging,
cerebrospinal ﬂuid leak, prior brain hemorrhage and/or intracranial aneurysms, or history of stroke or
transient ischemic attack
† ULN = upper limit of normal; LLN = lower limit of normal
doi:10.1371/journal.pone.0161821.t001
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general set to our real world population to determine eligibility. If variables were missing, we
assumed the patient would be eligible for that criterion.
Data acquisition and definitions
We extracted demographics, CHC characteristics, and laboratory values from the patients’
medical records on a pre-designed case report form. Baseline variables were collected at the
start of treatment not exceeding one year prior to treatment. Baseline concomitant medication
was collected prior to possible medication switch for expected interactions. Data was collected
until 24 weeks after cessation of treatment. We collected whether patients had a history of or
current decompensated liver disease, this was defined as a history or signs of ascites, variceal
bleed or hepatic encephalopathy. Effectiveness was defined as sustained virological response
(SVR): undetectable hepatitis C virus RNA 12 or 24 weeks after cessation of treatment. Safety
data included adverse events (AEs) and serious adverse events (SAEs). AEs were defined as any
event that required 1) dose reduction of peg-interferon or ribavirin, 2) prescription of medica-
tion or 3) referral. We used the FDA definition for SAEs.[12] We categorized AEs and SAEs by
common terminology criteria for adverse events (CTCAE version 4.0).[13] We recorded data
anonymously in an Access database (Microsoft Access 2007).
Outcomes and analysis
The primary outcomes were SVR and (S)AE rates, which were compared between patients eli-
gible and ineligible for registration trials. Furthermore, we identified criteria that affected eligi-
bility and were associated with the outcomes. Analyses were performed on an intention to treat
population, where telaprevir and boceprevir treated patients were pooled. To check validity of
pooling, we compared baseline characteristics and treatment outcomes between telaprevir and
boceprevir patients.[14]
SVR rates, and (S)AE rates were analyzed with χ2 (or Fisher exact if counts<5), and Mann-
Whitney U test (median number of (S)AEs). For analyses on SVR, we separated patients into
two groups based on expected similar effectiveness: 1) treatment-naive and relapse patients,
and 2) patients with a prior non-response, viral breakthrough or early discontinuation [15]; for
safety outcomes this distinction was not made. We used frequency counts to identify most
important eligibility criteria. To study the association of criteria and outcomes, we performed
log binomial regression (relative risk) or poisson regression.[16] To explore the validity of our
generated set of the least stringent criteria from the protocols, we performed three sensitivity
analyses: a) with most stringent criteria (S2 Table), b) with strictest exclusion of co-morbidity,
and c) with the most important factor for exclusion eliminated from the criteria set. All analy-
ses were two-sided with a significance level of p<0.05, and performed in SPSS (IBM SPSS Sta-
tistics 20).
Results
Population
We identified 489 treated patients from 45 centers, and we excluded 22 patients (Fig 1). Centers
treated a median of 8 patients (range 1–53). Overall, the majority of patients (60%) was treat-
ment naive, 52% had advanced fibrosis or cirrhosis and 5% had a history of decompensated
liver disease. Baseline characteristics are shown in Table 2. We pooled telaprevir (n = 265) and
boceprevir (n = 202) data, as there were no significant differences in characteristics and treat-
ment outcomes between patients (S3 and S4 Tables).
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Registration trials and outcomes eligible vs. ineligible
Our search yielded eight trials of telaprevir and boceprevir [17–24], and five registration trials
were included. (S1 Table). [22–24] On the basis of the general criteria (Table 1), 47% of patients
treated in real world practice would be excluded from registration trials. We than compared
the eligible to ineligible population with respect to safety parameters. We found that ineligible
patients had significantly more SAEs compared to eligible patients (27% vs. 11%, p<0.001)
(Fig 2). A total of 37 SAEs occurred in 28 eligible patients (1 patient died due to an accident),
compared to 103 SAEs which occurred in 60 ineligible patients (7 patients died) (S5 Table).
Also, after excluding patients with a history of decompensated liver disease (n = 24) from the
analysis, ineligible patients had significantly higher SAE rates (24% vs. 11%, p<0.001). Further,
ineligible patients had a higher median number of AEs and SAEs (p = 0.039 and p<0.001
respectively, S6 Table). The incidence of some typical hepatic or therapy related (S)AEs (ane-
mia, thrombopenia and hepatobiliary events) were significantly higher in the ineligible patients
(Fig 3).
We found (non-significant) lower SVR rates in ineligible patients. Two sensitivity analyses
detected lower SVR rates in ineligible patients (treatment naive–relapse group): when applying
most strict criteria (81% vs. 67%, p = 0.01) or when most stringent exclusion of patients with
co-morbidity was done (76% vs. 65%, p = 0.02). We observed no difference in SVR in the third
Fig 1. Study flowchart. The flowchart shows both enrollment of patients in all centers and assessment of eligibility for registration
trials in this study.
doi:10.1371/journal.pone.0161821.g001
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sensitivity analysis, where we excluded concomitant medication from the criteria set (Fig 4).
No significant differences in effectiveness were found in the non-responder group (S1 Fig).
Criteria for ineligibility
Most important criteria for ineligibility were related to co-morbidity and signs or history of
hepatic decompensation. In 220 ineligible patients, main reason for exclusion was the use of
prohibited concomitant medication (n = 65), followed by anemia (n = 25), psychiatric co-mor-
bidity (n = 24), and current or history of decompensated liver disease (n = 24). Median number
of exclusion criteria within a patient was 1 (range 1–6). Univariable analysis showed most
important criteria associated with lack of SVR, i.e. current or history of decompensated liver
disease (RR 0.66), platelet count (RR 0.58), albumin (RR 0.49), bilirubin (RR 0.58) and neutro-
phil count (RR 0.55). Similar criteria were associated with a higher risk on an SAE: a history of
decompensated liver disease (RR 1.81), platelet count (RR 1.45), albumin (RR 2.03), bilirubin
(RR1.89), hemoglobin (RR 1.72), malignancy (RR 2.31) and presence of cardiac disease (RR
1.97). Outcomes of these analyses are depicted in Table 3.
Table 2. Baseline characteristics.
Characteristic Overall (n = 467) Eligible (n = 247) Ineligible (n = 220) p-value
Age, y–mean (range) 51 (19–77) 50 (22–77) 52 (19–70) 0.07
Male sex–n (%) 319 (68) 170 (69) 149 (68) 0.80
White race–n (%)a 321 (89) 173 (91) 148 (88) 0.08
HCV genotype–n (%) 0.23
•Genotype 1 indeterminate
•Genotype 1a
•Genotype 1b
• 86 (18)
• 226 (48)
• 155 (33)
• 49 (20)
• 122 (49)
• 76 (31)
• 37 (17)
• 104 (47)
• 79 (36)
Previous responseb 0.81
• Naive
• Relapse
• Nonresponse
• Viral breakthrough
• Early discontinuation
• 273 (60)
• 76 (17)
• 78 (17)
• 16 (4)
• 11 (2)
• 142 (59)
• 45 (19)
• 41 (17)
• 9 (4)
• 5 (2)
• 131 (62)
• 31 (15)
• 37 (18)
• 7 (3)
• 6 (3)
Current or history of decompensated liver disease–n (%) 24 (5) 0 (0) 24 (11) <0.001
Metavir score F3-4c 161 (52) 66 (42) 95 (63) <0.001
Laboratory valuesd
Haemoglobin g/dL—mean (SD) 9.1 (0.9) 9.2 (0.8) 9.0 (1.0) 0.02
Leucocyte count x109/L—mean (SD) 6.7 (2.2) 7.0 (2.1) 6.4 (2.2) 0.003
Neutrophil count x109/L—mean (SD) 3.5 (1.5) 3.6 (1.5) 3.3 (1.5) 0.22
Platelet count x109/L–mean (range) 192 (24–764) 207 (90–388) 175 (24–764) <0.001
Albumin g/dL–mean (range) 4.1 (2.4–5.1) 4.3 (3.3–5.1) 4.0 (2.4–5.1) <0.001
Total bilirubin g/dL–median (IQR) 10.0 (7–14) 9 (7–13) 11 (8–16) <0.001
Child Pugh (CP) scoree 0.001
• A–n (%)
• B–n (%)
• C–n (%)
• 212 (95)
• 11 (5)
• 0 (0)
• 107 (100)
• 0 (0)
• 0 (0)
• 105 (91)
• 11 (10)
• 0 (0)
a Race: available in 360 patients;
b Previous response: available in 454 patients;
c Metavir score: available in 308 patients;
d Lab values >10%missings in: neutrophil count, albumin;
e CP-score (assumed no ascites and hepatic encephalopathy at start of treatment): available in 223 patients
doi:10.1371/journal.pone.0161821.t002
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Discussion
This study sheds doubt on the generalizability of registration trials to the real world CHC pop-
ulation. In our study, one of the key findings is that nearly half of treated CHC patients would
be ineligible for registration trials. Most important exclusion criteria relate to signs or history
of hepatic decompensation and co-morbidity (cardiac disease, anemia, malignancy and neutro-
penia). Patients meeting those exclusion criteria developed more SAEs (RR between 1.45 and
2.31) and were less likely to reach SVR (RR between 0.49 and 0.66), especially when strict crite-
ria were used. Vice versa, eligible patients had SVR and SAE rates comparable to published tri-
als.[17–21] Altogether, this indicates that results from registration trials are only generalizable
to the real world patients who fulfill the eligibility criteria. Translating results originating from
registration trials to patients that would be ineligible should be done with caution.
Fig 2. Safety in real world patients who would be eligible and ineligible for registration trials. The bars
represent the proportion of patients who experienced a serious adverse event or adverse event in patients
eligible or ineligible for registration trials.
doi:10.1371/journal.pone.0161821.g002
Fig 3. Incidence of specific (serious) adverse events in eligible and ineligible patients. The bars represent the incidence of
various categories of (serious) adverse events between patients eligible and ineligible for registration trials. The asterix (*) marks
significant differences between eligible and ineligible patients.
doi:10.1371/journal.pone.0161821.g003
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The difference between registration trials and real world reflects a ‘development paradox’.
Drugs are developed through a phase II-III program that targets easy-to-treat patients, while in
the real world difficult-to-treat patients are prioritized for treatment.[1, 25, 26] The sequence
of drug development starting with easy-to-treat patients seems appropriate, but the final hurdle
to perform trials that specifically target difficult-to-treat patients is often sidestepped or delayed
until after market authorization. As a result, this population who has a clear treatment indica-
tion is exposed to DAAs in the real world, without proper data on efficacy and toxicity.[27]
This results in an increased proportion of adverse events, dropouts and hence lower effective-
ness.[28] Our results support the ‘development paradox’ and provide reasons why real world
outcomes do differ from registration trials.
Our data on limited generalizability of registration trials accords with the literature. An
increased likelihood for SAEs in patients with a history of decompensated cirrhosis who would
have been excluded from registration trials was reported in a large CHC cohort (n = 2084). [9]
Some 30–47% of compensated cirrhotic patients treated with first-generation protease inhibi-
tors would be ineligible for registration trials, and this study showed unexpected high SAE
rates in that population.[7] In addition, a study on ledipasvir/sofosbuvir in advanced liver dis-
ease patients, published after FDA and EMA approval, reported much higher SAE rates (23%)
compared to registration trials (3%). [29] For another CHC regimen, paritaprevir/ritonavir,
ombitasvir and dasabuvir, the FDA label changed within one year following approval based on
review of adverse events. This regime is now contra-indicated in patients with Child-Pugh B
cirrhosis. [30] It is likely that this could have been prevented if these patients had been trialed
prior to approval of the regimen. There is literature that suggests that serious adverse events
might be related to disease course instead of therapy.[31] Nonetheless, timely controlled
Fig 4. Effectiveness in real world treatment naive and relapse patients who would be eligible and ineligible for registration trials. Primary and
sensitivity analyses on effectiveness of therapy in eligible vs. ineligible naive and relapse patients (n = 348). The bars represent the proportion of
patients who reached a sustained virological response (SVR) within the groups. For sensitivity analyses different criteria sets are used to determine
eligibility of patients, hence different numbers of patients in both groups.
doi:10.1371/journal.pone.0161821.g004
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studies in CHC patients with decompensated liver disease are necessary to accurately gauge
risk-benefit balance for these individual patients.
Here, we used the first-generation protease inhibitor treated patients as an example cohort.
We believe that our results are also applicable to new generation DAAs, because eligibility cri-
teria of registration trials are comparable to the set used in the current study (S7 Table). [31–
37] Indeed, a Canadian HIV/HCV cohort, found that up to 94% of patients from that cohort
would be ineligible for registration trials with new generation DAAs.[10] Furthermore a real
world cohort showed that liver decompensation and SAEs during sofosbuvir containing regi-
mens were associated with lower baseline albumin and higher total bilirubin, which are general
exclusion criteria. [38] As toxicity of new generation DAAs decreases, the difference between
trials and real world might become smaller, however with the high ineligibility rate of real
world patients, generalization of results remains difficult.
Limited generalizability of registration trials is also seen in other liver diseases such as hepa-
tocellular carcinoma (HCC) and HBV infection. For example, sorafenib was approved for
HCC treatment, on the basis of studies that excluded Child-Pugh B and C cirrhotic patients.
[39, 40] A real world cohort reported significantly decreased overall survival with sorafenib in
Child-Pugh B compared to Child-Pugh A cirrhotics.[41] Likewise, post-marketing studies in
entecavir for chronic HBV infection show lower proportions of ALT normalization than was
shown in registration trials. [42]
Our study comes with strengths and limitations. Strengths of this study are the nationwide
and multicenter character, resulting in a large and representative real world cohort. Limitations
of this study are the retrospective character that resulted in (some) missing values. We handled
this conservatively, by classifying the missing value as eligible for that criterion. Furthermore,
Table 3. Top criteria which impact trial eligibility.
Criterion n % of ineligible
patients
RR on SVR(95%
CI)
RR on SAE(95%
CI)
Prohibited comedication listed in protocols 65 30 0.99 (0.70–1.39) 1.17 (1.00–1.38)
Hemoglobin <12 g/dL (females) or <13 g/dL (males) 25 11 0.69 (0.46–1.02) 1.72 (1.14–2.60)
Presence of severe psychiatric disease 24 11 1.27 (0.67–2.40) 1.03 (0.84–1.72)
Current or history of ascites, encephalopathy or bleeding varices 24 11 0.66 (0.44–0.97) 1.81 (1.17–2.81)
Platelet count < 90 x109/L 23 11 0.58 (0.41–0.82) 1.45 (1.01–2.08)
Presence of hemophilia 23 11 1.42 (0.71–2.85) 4.51 (0.66–30.93)*
Serum albumin < 3.3 g/dL 22 10 0.49 (0.36–0.68) 2.03 (1.23–3.37)
Total bilirubin > 1,8x ULN† 16 7 0.58 (0.39–0.86) 1.89 (1.08–3.29)
TSH > 1.2 x ULN or 0.8x LLN† 14 6 0.71 (0.41–1.22) 1.34 (0.36–4.90)*
Active malignant disease or malignant disease in past 5 years (except basal cell
carcinoma)
14 6 1.02 (0.50–2.09) 2.31 (1.14–4.66)
Central nervous system disorder present 13 6 0.78 (0.43–1.43) 1.18 (0.82–1.70)
Signiﬁcant cardiac disease present 12 6 1.46 (0.54–3.91) 1.97 (1.01–3.86)
Presence of auto-immune disease 11 5 1.34 (0.51–3.55) 1.50 (0.87–2.58)
Absolute neutrophil count < 1.2 x109/L 9 4 0.55 (0.34–0.90) 1.62 (0.25–10.43)*
Ultrasound with no signs of HCC 6 3 0.74 (0.33–1.66) 1.64 (0.74–3.65)
Creatinine clearance  50 ml/min 5 2 0.63 (0.30–1.30) 2.05 (0.70–6.01)
AST 10 x ULN† 5 2 0.61 (0.29–1.26) 1.01 (0.65–1.57)
Presence of another liver disease 5 2 0.60 (0.29–1.24) -
* Poisson regression when log binomial regression did not converge
† ULN = upper limit of normal; LLN = lower limit of normal
doi:10.1371/journal.pone.0161821.t003
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chart review may result in reporting bias, but we used strict definitions to reduce this. Another
limitation is that patients received first-generation protease inhibitors, peginterferon and riba-
virin, which may increase the potential for toxicity. However, we think that our results are also
valid for new generation DAAs.
In conclusion, nearly half of CHC patients treated in real world practice would be ineligible
for registration trials. In these patients we found impaired safety and effectiveness related to
specific eligibility criteria (hepatic decompensation, co-morbidity). Prior to regulatory
approval, new drugs should also be studied in the difficult-to-treat population, including
patients with hepatic decompensation and co-morbidity, to genuinely assess the benefits and
risks of treatment in the real world population.
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